Article

Multimodal histopathologic models stratify hormone receptor-positive early breast cancer

2024-02-28

Abstract excerpt

For patients with hormone receptor-positive, early breast cancer without HER2 amplification, multigene expression assays including Oncotype DX ® recurrence score (RS) have been clinically validated to identify patients who stand to derive added benefit from adjuvant cytotoxic chemotherapy. However, cost and turnaround time have limited its global adoption despite recommendation by practice guidelines. We investig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0bddfaed-ccc8-57b9-b806-fc6f143a8569
DOI: 10.1101/2024.02.23.581806

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multimodal histopathologic models stratify hormone receptor-positive early breast cancerDOI 10.1101/2024.02.23.581806Read

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read

Deep Learning on Histopathological Images to Predict Breast Cancer Recurrence Risk and Chemotherapy BenefitSemantic proximity Read

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read

Prediction of OncotypeDX recurrence score using H&E stained WSI imagesSemantic proximity Read

Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerSemantic proximity Read

Deep learning from HE slides to predict the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancerSemantic proximity Read

Predicting MammaPrint Recurrence Risk from Breast Cancer Pathological Images Using a Weakly Supervised TransformerSemantic proximity Read

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read

Assessing the risk of recurrence in early-stage breast cancer through H&E stained whole slide imagesSemantic proximity Read

MRI-based Prognostic Model in Early-Stage HR+/HER2- Breast CancerSemantic proximity Read